Inactive Instrument

Biocorrx Inc Stock Other OTC

US09073C1062

Healthcare Facilities & Services

BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees

Sector

Healthcare Facilities & Services

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	11.62M 10.17M 9.38M 8.67M 16.47M 1.11B 16.74M 112M 44.01M 545M 43.63M 42.69M 1.89B	P/E 2024	-0.78x	P/E 2025	-1.56x
Enterprise Value	13.62M 11.92M 10.99M 10.17M 19.3M 1.3B 19.62M 132M 51.59M 639M 51.14M 50.04M 2.21B	EV / Sales 2024	1,004x	EV / Sales 2025	11.4x
Free-Float	38.64%	Yield 2024 *	-	Yield 2025	-

05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
11-14	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-28	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
25-05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-30	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
24-11-14	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-13	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
24-08-15	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
24-05-16	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
24-04-03	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
24-04-02	BioCorRx Reports Business Update for 2023	AQ

Manager	Title	Age	Since
Lourdes Felix CEO	Chief Executive Officer	58	2020-11-08
Louis Lucido PSD	President	77	2024-01-04

Director	Title	Age	Since
Lourdes Felix BRD	Director/Board Member	58	2013-03-06
Kent Emry CHM	Chairman	57	-
Louis Lucido BRD	Director/Board Member	77	2019-02-28

Biocorrx Inc Stock Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

Valuation: Biocorrx Inc

Latest news : Biocorrx Inc

Press Releases: Biocorrx Inc

Quotes and Performance

Managers and Directors: Biocorrx Inc

Other Healthcare Facilities & Services

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORRX INC	-15.84%	+6.09%	-	-	11.62M
CVS HEALTH CORPORATION	-1.59%	-1.82%	+54.23%	+48.23%	133B
HCA HEALTHCARE, INC.	-0.39%	-0.36%	+8.08%	+38.30%	91.09B
FRESENIUS SE & CO. KGAA	-0.42%	+2.90%	+0.55%	+71.35%	27.23B
QUEST DIAGNOSTICS INCORPORATED	-0.08%	-3.56%	+19.83%	+48.86%	23.05B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-1.75%	-1.11%	-20.93%	-25.61%	20.25B
TENET HEALTHCARE CORPORATION	+0.25%	+1.50%	+20.64%	+149.54%	17.77B
DAVITA INC.	-0.54%	-2.31%	+61.79%	+121.31%	14.81B
REDE D'OR SÃO LUIZ S.A.	+3.14%	-1.07%	+3.29%	+10.78%	14.51B
FRESENIUS MEDICAL CARE AG	-0.38%	+4.37%	-11.32%	-2.43%	12.86B
Average	-1.71%	+1.73%	+15.13%	+51.15%	39.43B
Weighted average by Cap.	-0.58%	+1.58%	+25.92%	+48.04%

	2024	2025
Net sales	7.66K 6.71K 6.18K 5.72K 10.86K 732K 11.04K 74.05K 29.03K 359K 28.78K 28.15K 1.24M	797K 697K 643K 595K 1.13M 76.1M 1.15M 7.7M 3.02M 37.37M 2.99M 2.93M 129M
Net income	-5.11M -4.47M -4.12M -3.81M -7.23M -487M -7.35M -49.33M -19.34M -239M -19.17M -18.75M -829M	-3.44M -3.01M -2.78M -2.57M -4.87M -328M -4.96M -33.24M -13.03M -161M -12.91M -12.64M -559M
Net Debt	2.72M 2.38M 2.19M 2.03M 3.85M 259M 3.92M 26.26M 10.29M 127M 10.2M 9.98M 441M	2M 1.75M 1.61M 1.49M 2.84M 191M 2.88M 19.33M 7.58M 93.81M 7.51M 7.35M 325M